Evidence map›Paper›PMID 31607205›Full record

Trial reportJournal of the American Heart Association2019

Effects of Simvastatin on Augmentation Index Are Transient: Outcomes From a Randomized Controlled Trial.

Adam D Gepner, Karen Lazar, Carol Van Hulle, Claudia E Korcarz, Sanjay Asthana, Cynthia M Carlsson

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Effects of simvastatin on white matter integrity in healthy middle-aged adults.Annals of clinical and translational neurology · 2021
    Trial
  2. Trial
  3. Article
  4. Review
  5. Vascular Aging: Assessment and Intervention.Clinical interventions in aging · 2023
    Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Adam D GepnerWilliam S. Middleton Memorial Veterans Hospital Madison WI.
Karen LazarWilliam S. Middleton Memorial Veterans Hospital Madison WI.
Carol Van HulleWilliam S. Middleton Memorial Veterans Hospital Madison WI.
Claudia E KorcarzDepartment of Medicine School of Medicine and Public Health University of Wisconsin Madison WI.
Sanjay AsthanaWilliam S. Middleton Memorial Veterans Hospital Madison WI.
Cynthia M CarlssonWilliam S. Middleton Memorial Veterans Hospital Madison WI.
University of Wisconsin–Madison · USWilliam S. Middleton Memorial Veterans Hospital · US

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sanjay Asthana · 2019 to 2026
$34.5M
Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI HART, MICHAEL N · 2009 to 2018
$16.2M
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for ADR01AG031790 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CARLSSON, CYNTHIA M · 2009 to 2013
$1.6M
NCATS NIH HHS UL1 TR002373NIA NIH HHS P30 AG062715NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG031790
6 · The paper itself

Abstract

Background Statins improve endothelial function, but their effects on arterial stiffness and aortic blood pressure in middle-aged adults are uncertain. Methods and Results This was a prospective, randomized, double-blind, placebo-controlled trial of middle-aged (40-72 years old) adults who were randomly assigned to receive simvastatin 40 mg (n=44) or placebo (n=44) daily for 18 months to evaluate impact on dementia-related biomarkers (primary end points) and measures of vascular health (secondary end points). This analysis focuses on the predetermined secondary end points of changes in central aortic blood pressure, aortic augmentation index, and brachial artery flow-mediated dilation. Measurements were performed at baseline and after 6, 12, and 18 months. Multivariable models were used to identify predictors of these prespecified vascular end points. Study groups were similar at baseline; low-density lipoprotein cholesterol declined in the statin group but not in the placebo group (

Indexed as

AdultAgedBiomarkersBrachial ArteryCardiovascular DiseasesCholesterol, LDLCytokinesDouble-Blind MethodEndothelium, VascularFemaleFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedProspective StudiesBiomarkersCholesterol, LDLCytokinesHydroxymethylglutaryl-CoA Reductase InhibitorsSimvastatinarterial stiffnessatherosclerosislow‐density lipoprotein cholesterolrandomized controlled trialstatin therapy

Identifiers

PMID31607205
PMCPMC6818042
OpenAlexW2980179790

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.